Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2452822 | 0.90 | MEN1 (0.59) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL892211 | 0.85 | MEN1 (0.47) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL26321492 | 0.81 | MEN1 (0.43) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL25434536 | 0.81 | MEN1 (0.43) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL10168285 | 0.80 | MEN1 (0.40) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL891080 | 0.80 | MEN1 (0.50) | MEN1PABPC1KMT2ACA12CA1 | |
| Iodide SCHEMBL892222 | 0.79 | MEN1 (0.39) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL26321498 | 0.79 | ADORA2B (0.37) | MEN1PABPC1KMT2AADORA2BGLA | |
| SCHEMBL892341 | 0.79 | MEN1 (0.49) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL21711285 | 0.78 | ADORA2B (0.36) | MEN1PABPC1KMT2AADORA2BGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445915-B1 | 3-SUBSTITUTED-8-SUBSTITUTED-3H IMIDAZO[5,1-D][1,2,3,5-TETRAZIN-4-ONE COMPOUNDS AND THEIR USE | PHARMINOX LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| EP-2445915-B1 | 3-SUBSTITUTED-8-SUBSTITUTED-3H IMIDAZO[5,1-D][1,2,3,5-TETRAZIN-4-ONE COMPOUNDS AND THEIR USE | PHARMINOX LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| US-9024018-B2 | 3-substituted-8-substituted-3H-imidazo[5,1-d][1,2,3,5]tetrazin-4-one compounds and their use | PHARMINOX LIMITED (GB) | 2015-05-05 | — | — | US | disclosed |
| US-9024018-B2 | 3-substituted-8-substituted-3H-imidazo[5,1-d][1,2,3,5]tetrazin-4-one compounds and their use | PHARMINOX LIMITED (GB) | 2015-05-05 | — | — | US | disclosed |
| US-9024018-B2 | 3-substituted-8-substituted-3H-imidazo[5,1-d][1,2,3,5]tetrazin-4-one compounds and their use | PHARMINOX LIMITED (GB) | 2015-05-05 | — | — | US | disclosed |
| EP-2445915-A1 | 3-SUBSTITUTED-8-SUBSTITUTED-3H IMIDAZO[5,1-D][1,2,3,5-TETRAZIN-4-ONE COMPOUNDS AND THEIR USE | Pharminox Limited (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20120083513-A1 | 3-Substituted-8-Substituted-3H-Imidazo[5,1-d][1,2,3,5]tetrazin-4-one Compounds and Their Use | PHARMINOX LIMITED (GB) | 2012-04-05 | — | — | US | disclosed |
| US-20120083513-A1 | 3-Substituted-8-Substituted-3H-Imidazo[5,1-d][1,2,3,5]tetrazin-4-one Compounds and Their Use | PHARMINOX LIMITED (GB) | 2012-04-05 | — | — | US | disclosed |
| US-20120083513-A1 | 3-Substituted-8-Substituted-3H-Imidazo[5,1-d][1,2,3,5]tetrazin-4-one Compounds and Their Use | PHARMINOX LIMITED (GB) | 2012-04-05 | — | — | US | disclosed |
| WO-2010149968-A1 | 3-SUBSTITUTED-8-SUBSTITUTED-3H IMIDAZO[5,1-D][1,2,3,5-TETRAZIN-4-ONE COMPOUNDS AND THEIR USE | PHARMINOX LIMITED (GB) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010149968-A1 | 3-SUBSTITUTED-8-SUBSTITUTED-3H IMIDAZO[5,1-D][1,2,3,5-TETRAZIN-4-ONE COMPOUNDS AND THEIR USE | PHARMINOX LIMITED (GB) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083513-A1 | 3-Substituted-8-Substituted-3H-Imidazo[5,1-d][1,2,3,5]tetrazin-4-one Compounds and Their Use | MKI67, CCNA1, CCNI | MEN1 937/4885PABPC1 3125/4885KMT2A 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.